This project has been initiated in order to develop a team approach to clarifying the mechanisms by which tumors affect the skeleton and cause disastrous clinical consequences such as hypercalcemia, bone pain and susceptibility to fracture. It is our contention that tumors exert their effects via production of osteotropic factors. Recent studies by ourselves and others indicate that these factors are heterogeneous and their complete identification and characterization will require a broadly based approach involving investigators with expertise in widely disparate areas.
The specific aims of this research are to identify the tumor products which affect bone cell function and lead to osteolytic metastiasis and hypercalcemia and to detemine how these factors interact with each other in causing bone destruction and hypercalcemia. Our plan is primarily to use in vitro techniques of cell culture to identify factors which affect bone cell function using sensitive bioassays for bone resorption. We intend to characterize the role of the tumor derived transforming growth factors, the PTH-like factors associated with hypercalcemia, and the family of osteoclast activating factors produced by hematologic malignancies. Since the expertise required to identify and clarify these heterogeneous factor will require the attention of investigators with different types of skills, a team approach will be used to unite a number of diverse approaches around the tightly focused goal of clarifying the mechanisms responsible for bone destruction in various tumor types. (P)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA040035-02
Application #
3093757
Study Section
Cancer Special Program Advisory Committee (CAK)
Project Start
1985-09-30
Project End
1989-01-31
Budget Start
1987-04-01
Budget End
1988-01-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Arnold Egloff, Shanna A; Du, Liping; Loomans, Holli A et al. (2017) Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget 8:722-741
Arnold, Shanna A; Loomans, Holli A; Ketova, Tatiana et al. (2016) Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis 33:29-44
Preston Campbell, J; Mulcrone, P; Masood, S K et al. (2015) TRIzol and Alu qPCR-based quantification of metastatic seeding within the skeleton. Sci Rep 5:12635
Sharma, Ramaswamy; Williams, Paul J; Gupta, Anjana et al. (2015) A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, ?-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget 6:21589-602
Seeley, Erin H; Wilson, Kevin J; Yankeelov, Thomas E et al. (2014) Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease. Bone 61:208-16
Johnson, Rachelle W; Merkel, Alyssa R; Page, Jonathan M et al. (2014) Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis 31:945-59
Ding, Hao; Nyman, Jeffry S; Sterling, Julie A et al. (2014) Development of Raman spectral markers to assess metastatic bone in breast cancer. J Biomed Opt 19:111606
Hansen, Amanda G; Arnold, Shanna A; Jiang, Ming et al. (2014) ALCAM/CD166 is a TGF-?-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res 74:1404-15
Waning, David L; Mohammad, Khalid S; Guise, Theresa A (2013) Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell 24:407-9
Jin, Renjie; Sterling, Julie A; Edwards, James R et al. (2013) Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One 8:e60983

Showing the most recent 10 out of 210 publications